Hormonal
Weekly subcutaneous semaglutide (up to 1 mg) as an adjunct to automated insulin delivery significantly improves glycemic control (increasing time in range by 4.8 percentage points) and reduces body weight in adults with type 1 diabetes without increasing hypoglycemia risk.
If you have Type 1 Diabetes and use an automated insulin delivery system, adding weekly semaglutide (up to 1 mg) can significantly improve your time in range and help with weight loss without increasing the risk of low blood sugar. While gastrointestinal side effects are common, they are usually manageable, and the risk of ketosis, though present, can be mitigated with education and monitoring. This is a viable option, especially for those with higher BMI.
Compared to placebo, semaglutide increased time in the target range by a mean 4.8 (s.d. = 7.6) percentage points (P = 0.006), without increasing the time spent below 3.9 mmol l−1 (P = 0.19) or below 3.0 mmol l−1 (P = 0.65)... We conclude that semaglutide improves glycemic control with automated insulin delivery compared to placebo.
Why this rating
Double-blind, randomized, crossover trial with rigorous statistical analysis and clear primary endpoint achievement.
Source
Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial
Melissa‐Rosina Pasqua et al. · Nature Medicine · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →